TGA issues warning over GLP-1-based drugs' potential to cause rare eye disorder Fri 24 Jul 2026 at 11:13am In short: The Therapeutic Goods Administration is warning of a rare but serious eye disorder that could be caused by GLP-1-based drugs
Studies have already suggested that Semaglutide may improve cardiovascular health, such as blood pressure and cholesterol levels, offering additional advantages to individuals struggling with obesity-related complications
Multi-omics analysis reveals neuroinflammation, activated glial signaling, and dysregulated synaptic signaling and metabolism in the hippocampus of aged mice
However, there are some key differences between the two medications
This is a short chain of amino acids
Once-Weekly Injections: Convenient dosing with long-acting results, easily fitting into your weekly routine